For the quarter ending 2026-03-31, JAGX made $20,272K in revenue. -$7,015K in net income. Net profit margin of -34.60%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue, net | 20,272 | 3,235 | 3,083 | 2,979 |
| Cost of product revenue | 1,158 | 2,200 | 532 | 527 |
| Research and development | 3,928 | 14,313 | 3,658 | 3,265 |
| Sales and marketing | 896 | 2,278 | 1,997 | 2,467 |
| General and administrative | 4,108 | 4,886 | 4,134 | 4,727 |
| Impairment loss on indefinite-lived intangible assets | - | 800 | - | - |
| Total operating expenses | 10,090 | 24,477 | 10,321 | 10,986 |
| Income (loss) from operations | 10,182 | -21,242 | -7,238 | -8,007 |
| Interest income (expense) | 699 | 132 | 6 | -15 |
| Gain on extinguishment of debt | -628 | 23 | - | -1,822 |
| Changes in fair value of freestanding and hybrid financial instruments designated at fair value option | 337 | 1,545 | 2,310 | 1,068 |
| Other income (expense) | 205 | -297 | -94 | 322 |
| Income (loss) before income tax expense | 8,723 | -23,193 | -9,648 | -10,560 |
| Income tax expense | 0 | 0 | - | - |
| Net income (loss) | 8,723 | -23,193 | -9,648 | -10,560 |
| Net loss attributable to noncontrolling interest | -126 | -183* | - | - |
| Stock dividends to preferred stockholders | 9,470 | - | - | - |
| Deemed dividend to preferred stockholders | 6,063 | 35* | - | - |
| Net loss attributable to common stockholders | - | -23,045* | - | - |
| Translation adjustments | - | -91* | - | - |
| Preferred returns to preferred stockholders | 331 | - | - | - |
| Net comprehensive loss attributable to common stockholders | - | -23,137 | - | - |
| Net loss attributable to common stockholders | -7,015 | - | - | - |
| Basic EPS | -13.6 | -9.92 | -6.28 | -10.26 |
| Diluted EPS | -13.6 | -9.92 | -6.28 | -10.26 |
| Basic Average Shares | 515,788 | 2,332,401* | 1,513,178 | 1,014,783 |
| Diluted Average Shares | 515,788 | 2,332,401* | 1,513,178 | 1,014,783 |
Jaguar Health, Inc. (JAGX)
Jaguar Health, Inc. (JAGX)